GSK India Q1 FY27: Profitable growth as innovation scales up

GlaxoSmithKline Pharmaceuticals Limited opened FY27 with a strong reported quarter. Standalone revenue for Q1 FY27 was 924 crore, up 15% year on year. Profitability improved as well. EBITDA rose 17% to 293 crore and EBITDA margin expanded 50 basis points to 31.7%. PAT came in at 253 crore, up 24%, with PAT margin improving 200 basis points to 27.6%.

Management positioned the quarter as a mix of execution in the core portfolio and continued portfolio transformation toward innovation and specialty. The company also highlighted that last year’s quarter had supply disruption related to a contract manufacturing organization, which created a favorable base. The CFO stated that this base effect likely added about 4% to 5% to the headline sales growth, implying underlying growth of about 9% to 10% for the quarter.

What drove the quarter: core brands plus a growing innovation block

GSK India framed its operating model around three pillars: general medicines, vaccines (including established pediatric vaccines and adult vaccination), and specialty products that include respiratory and oncology assets.

In general medicines, management pointed to competitive performance across key brands, supported by market share and execution. The investor deck highlighted brands such as Augmentin, Calpol, T-Bact and Ceftum delivering competitive value growth and market share metrics in their represented markets.

The innovation portfolio is still a small part of the topline, but it is scaling. Management stated that innovation products contributed 7% of total sales in Q1 FY27, up from 4% in the same quarter last year. They also quantified its impact on growth, noting that innovation contributed about four percentage points of the headline growth.

Within vaccines, the company continues to emphasize leadership in the private pediatric market and category creation in adult vaccination. Shingrix was repeatedly called out as a key driver. Management said Shingrix grew about 60% to 65% year on year in Q1 and that quarterly volumes are now around 45,000 to 50,000 doses. The MD also confirmed that Shingrix has crossed 100 crore on a MAT basis.

In specialty respiratory, management said Nucala has seen a significant ramp-up in new patient additions. They cited around 600 patients on active treatment at any given point and indicated that new patient additions per month in Q1 FY27 were roughly double versus last year. For Trelegy Ellipta, management said the product continues to maintain monthly unit volumes of around 10,000 to 12,000 despite generic competition.

Financial summary

Notes: Management stated a favorable base effect of about 4% to 5% on sales growth due to prior year CMO disruption. PAT also included a one-off dividend from the 100% subsidiary, Biddle Sawyer; excluding this, management said PAT growth would have been about 17%.

Margins improved, despite higher investments in the quarter

The EBITDA margin expansion was attributed primarily to better gross margins. Management stated gross margin improved about 150 basis points, helped by pricing and favorable mix. They also acknowledged headwinds from higher costs on imported purchases due to rupee depreciation, but net impact still resulted in a better gross margin profile.

The quarter saw elevated operating expenditure. Selling and administration as a percentage of sales increased by about 1 percentage point. Management described this as a deliberate front-loading of investments, including focused promotional and scientific engagement activities ahead of the seasonally important September quarter. The CFO added that the spend spike is more about phasing than a permanent step-up, and that investment ratios are expected to moderate back toward historical trends in subsequent quarters. He also stated that the company expects EBITDA margins to be roughly in the 34% range, similar to last year, as the year progresses.

Pipeline and launch cadence: focus on oncology, adult vaccines and liver disease

Management reiterated alignment with the global parent’s priorities around growth, pipeline acceleration and simplification. A key element of the India strategy is to reduce launch lag by participating in global clinical trials and accelerating the flow of innovative assets into the market.

On upcoming launches, the company highlighted Blenrep, Omjjara and Arexvy as part of the launch runway. For Blenrep specifically, management stated that the product has received CDSCO approval and is expected to be launched in FY27, most likely in Q2 or Q3.

The company also discussed early progress in oncology. Jemperli and Zejula were described as gaining traction, with management stating that the two products together have touched roughly 250 to 300 patients on a quarterly basis, and around 600 to 700 patients in the first six months of the calendar year.

On commercialization of Bepirovirsen for chronic hepatitis B, management did not provide a firm timeline in this quarter, but indicated that work is underway and that more details would be shared in subsequent quarters.

Key takeaways for investors

GSK India’s Q1 FY27 performance was strong on reported numbers, and management provided useful context on the base effect and one-off income that supported growth and PAT. The bigger strategic message was the continued shift in the portfolio. Innovation products are still a minority of sales, but their contribution is rising meaningfully, led by Shingrix and specialty assets in respiratory and oncology.

The next few quarters will likely be judged on two things: whether the general medicines base continues to grow competitively and whether the innovation block can keep scaling without materially diluting profitability. Management’s commentary suggests both priorities are being pursued in parallel, with a conscious approach to front-loading investments while aiming to keep margin outcomes broadly in line with recent years.